Oscar Health (OSCR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Election of eight director nominees to serve until the 2027 Annual Meeting, with all nominees recommended by the board.
Advisory vote on executive compensation (Say-on-Pay) is up for approval.
Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026 is proposed.
Additional business may be addressed if properly brought before the meeting.
Board of directors and corporate governance
Eight director nominees are presented for election, including Mark T. Bertolini, William J. Gassen III, Joshua Kushner, Laura Lang, David Alexander Plouffe, Siddhartha Sankaran, Mario Schlosser, and Vanessa Ames Wittman.
Executive compensation and say-on-pay
Shareholders are asked to approve, on an advisory basis, the compensation of named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Oscar Health
- Strong 2026 performance, favorable trends, and AI-driven integrity shape a stable outlook.OSCR
Goldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026 - Board transitions, robust growth, and all proposals approved; no Q&A from shareholders.OSCR
AGM 20264 Jun 2026 - Revenue and net income soared, membership surged, but regulatory risks persist.OSCR
Q1 20267 May 2026 - Proxy covers director elections, say-on-pay, auditor ratification, and robust governance practices.OSCR
Proxy filing23 Apr 2026 - Strong 2026 enrollment and robust risk management drive optimism amid regulatory shifts.OSCR
47th Annual Raymond James Institutional Investor Conference2 Mar 2026 - Record 2025 revenue and membership, but higher costs led to a net loss; 2026 targets profitability.OSCR
Q4 202510 Feb 2026 - AI, personalization, and expanded financial tools are key to driving real healthcare consumerism.OSCR
7th Annual Healthcare Symposium3 Feb 2026 - Q2 revenue up 46%, net income $56.2M, membership up 63%, and full-year guidance raised.OSCR
Q2 20242 Feb 2026 - Aims for 20% revenue CAGR and 5% margin by 2027, leveraging ACA, ICHRA, and technology.OSCR
Investor Day 20241 Feb 2026